Compare DSP Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.93 | 1.87 |
NAV | ₹39.10 | ₹39.64 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3178.53 Cr | ₹6459.82 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.93
1.87
NAV
₹39.10
₹39.64
Fund Started
12 Nov 2018
25 Jun 2018
Fund Size
₹3178.53 Cr
₹6459.82 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
1 Year | -5.23% | 3.14% |
3 Year | 21.16% | 27.34% |
5 Year | 15.60% | 17.86% |
1 Year
-5.23%
3.14%
3 Year
21.16%
27.34%
5 Year
15.60%
17.86%
Equity | 97.09% | 97.70% |
Cash | 2.91% | 2.30% |
Equity
97.09%
97.70%
Cash
2.91%
2.30%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 8.85% |
Cipla Ltd. | 8.63% |
Ipca Laboratories Ltd. | 7.76% |
Globus Medical Inc | 6.89% |
Laurus Labs Ltd. | 6.21% |
Illumina Inc. (USA) | 5.93% |
Cohance Lifesciences Ltd. | 5.27% |
Gland Pharma Ltd. | 5.10% |
Sai Life Sciences Ltd. | 4.99% |
Apollo Hospitals Enterprise Ltd. | 4.49% |
Sun Pharmaceutical Industries Ltd. | 12.83% |
Dr. Reddy's Laboratories Ltd. | 9.81% |
Cipla Ltd. | 8.00% |
Divi's Laboratories Ltd. | 7.48% |
Aurobindo Pharma Ltd. | 6.04% |
Lupin Ltd. | 5.70% |
Mankind Pharma Ltd. | 5.04% |
Alkem Laboratories Ltd. | 3.78% |
Syngene International Ltd. | 2.97% |
Cohance Lifesciences Ltd. | 2.68% |
Name | Jay Kothari | Dharmesh Kakkad |
Start Date | 07 Mar 2024 | 23 Feb 2021 |
Name
Jay Kothari
Dharmesh Kakkad
Start Date
07 Mar 2024
23 Feb 2021
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
12 Nov 2018
25 Jun 2018